Pfister S L, Kotulock D A, Campbell W B
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226, USA.
Hypertension. 1997 Jan;29(1 Pt 2):303-9. doi: 10.1161/01.hyp.29.1.303.
We recently identified a subgroup of rabbits (called nonresponders) that were deficient in vascular thromboxane A2 receptors. Thromboxane A2-mediated platelet aggregation was not different between responders and nonresponders. In the present study, we utilized these nonresponders as a model to study the relative contribution of the platelet and vascular thromboxane A2 receptors to the observed hemodynamic responses associated with arachidonic acid-induced sudden death. Mean arterial pressure was slightly but not significantly lower in the nonresponders compared with the responders. However, nonresponders were protected from arachidonic acid-induced sudden death. While 100% of the responders died at the 2.0 mg dose of arachidonic acid, only 27% of nonresponders died at this same dose. Administration of the thromboxane A2 mimetic U46619 (5 micrograms/kg IV) decreased blood pressure by 41 +/- 6 mm Hg in responders but had no effect in the nonresponders. The affinity and density of thromboxane A2 receptors in cultured aortic vascular smooth muscle cells obtained from both responders and nonresponders were assessed using radioligand binding. The Kd values were not different (4.4 +/- 1.0 versus 2.4 +/- 0.6 nmol/L, responder versus nonresponder). However, there was a significant decrease in the density of receptors from vascular smooth muscle cells of nonresponders (Bmax = 397 +/- 59 versus 157 +/- 59 fmol/10(6) cells, responder versus nonresponder, P < .01). U46619 produced a concentration-dependent increase in [3H]-thymidine incorporation into responder vascular smooth muscle cells but had no effect in the nonresponder cells. Using an anti-thromboxane A2 receptor antibody, we compared the amount of receptor expressed in aortic tissue obtained from responders and nonresponders. Consistent with the results observed with [3H]-thymidine uptake and radioligand binding assays, the expression of thromboxane A2 receptor protein was decreased in nonresponder compared with responder vascular tissue. Platelet thromboxane A2 receptor expression was not different. These studies demonstrate that the vascular smooth muscle cells of nonresponder rabbits are deficient in the thromboxane A2 receptor. Furthermore, the reduction in arachidonic acid-induced sudden death in nonresponders indicates that the vascular smooth muscle thromboxane A2 receptor mediates this effect.
我们最近鉴定出一组兔子(称为无反应者),它们缺乏血管血栓素A2受体。在有反应者和无反应者之间,血栓素A2介导的血小板聚集没有差异。在本研究中,我们利用这些无反应者作为模型,来研究血小板和血管血栓素A2受体对与花生四烯酸诱导的猝死相关的血流动力学反应的相对贡献。与有反应者相比,无反应者的平均动脉压略低但无显著差异。然而,无反应者可免受花生四烯酸诱导的猝死。当给予2.0mg剂量的花生四烯酸时,100%的有反应者死亡,而相同剂量下只有27%的无反应者死亡。静脉注射血栓素A2模拟物U46619(5微克/千克)可使有反应者的血压降低41±6mmHg,但对无反应者无影响。使用放射性配体结合法评估了从有反应者和无反应者获得的培养主动脉血管平滑肌细胞中血栓素A2受体的亲和力和密度。解离常数(Kd)值没有差异(4.4±1.0对2.4±0.6nmol/L,有反应者对无反应者)。然而,无反应者血管平滑肌细胞中的受体密度显著降低(最大结合量[Bmax]=397±59对157±59fmol/10⁶细胞,有反应者对无反应者,P<0.01)。U46619使[³H] - 胸腺嘧啶掺入有反应者血管平滑肌细胞的量呈浓度依赖性增加,但对无反应者细胞无影响。使用抗血栓素A2受体抗体,我们比较了从有反应者和无反应者获得的主动脉组织中表达的受体量。与[³H] - 胸腺嘧啶摄取和放射性配体结合试验观察到的结果一致,与有反应者血管组织相比,无反应者中血栓素A2受体蛋白的表达降低。血小板血栓素A2受体的表达没有差异。这些研究表明,无反应者兔子的血管平滑肌细胞缺乏血栓素A2受体。此外,无反应者中花生四烯酸诱导的猝死减少表明血管平滑肌血栓素A2受体介导了这种效应。